Rhenman & Partners Asset Management AB
SEC Form 13F institutional filer · CIK 0001599882
13F-HR · 32 reported holdings · 2026-03-31
Reported long-US-equity value
$0.41B
Top-10 concentration
60.2%
Rhenman & Partners Asset Management AB — $412M AUM allocation strategy
Rhenman & Partners Asset Management AB files SEC Form 13F and reports $412M of long US equity value across 32 reported holdings for 2026-03-31.
Its largest sector bet is Health Care 90.3%.
The top 10 holdings account for 60% of reported value — a conviction-weighted book concentrated in its best ideas. The sector and industry splits below are of the same reported value. Track quarter-over-quarter adds, trims, new positions and exits below — sourced from SEC 13F filings, public domain.
Rhenman & Partners Asset Management AB — latest SEC 13F insights
Reported long-US-equity value (13F AUM)
$412M
total across 32 reported holdings · 2026-03-31 · excludes shorts, cash, non-US
Top-10 concentration
60% of value
higher = narrower conviction; lower = spread / hedging
Biggest adds (shares)
+$BSX +194K sh · −$1.9M+$GILD +41.6K sh · +$7.9M+$IQV +26.5K sh · +$3.07M
Biggest trims (shares)
−$COO −278K sh · −$23.3M−$MDT −206K sh · −$20.6M−$KKR −148K sh · −$5.28M
Sector allocation (share of reported value)
- $XLVHealth Care90.3%—
- Other holdings9.7%—
each slice is a share of the reported long-US-equity value — smaller sectors and the rest of the book roll into “Other holdings”
Qtr shift = share-point change vs the prior quarter's filing — first period tracked for this filer; the column fills in with the next quarterly refresh.
Industry allocation (share of reported value)
- Biotechnology28.0%—
- Health Care Equipment25.3%—
- Health Care Distributors7.5%—
- Pharmaceuticals7.5%—
- Life Sciences Tools & Services7.1%—
- Health Care Services5.9%—
- Managed Health Care5.2%—
- Health Care Technology3.6%—
- Other holdings9.9%—
the finer GICS cut of the same book — same denominator — smaller industries roll into “Other holdings”
Qtr shift = share-point change vs the prior quarter's filing — first period tracked for this filer; the column fills in with the next quarterly refresh.
Top S&P 500 holdings
10 of 10 rows · sorted by Value ↓
| Ticker | Holding | Shares | Value | Δ QoQ | Weight |
|---|---|---|---|---|---|
| $BSX | Boston Scientific Corporation | 625K | $39.2M | +194K | 9.5% |
| $REGN | Regeneron Pharmaceuticals Inc | 48.1K | $37.2M | -13.3K | 9.0% |
| $LLY | Eli Lilly and Company | 33.7K | $31M | -8.51K | 7.5% |
| $CVS | CVS Health Corporation | 337K | $24.2M | +1K | 5.9% |
| $GILD | Gilead Sciences Inc | 168K | $23.4M | +41.6K | 5.7% |
| $TMO | Thermo Fisher Scientific Inc | 41.3K | $20.3M | +7.7K | 4.9% |
| $BIIB | Biogen Inc | 109K | $20M | +16.8K | 4.9% |
| $VRTX | Vertex Pharmaceuticals Incorporated | 43.5K | $19.4M | +9.23K | 4.7% |
| $ISRG | Intuitive Surgical Inc | 36.8K | $17M | -11.2K | 4.1% |
| $COR | Cencora Inc | 52.4K | $16.5M | -11K | 4.0% |
…and 22 more holdings in the full 13F filing (top positions only shown).
SEC Form 13F data sets · public domain · 45-day filing lag · >$100M AUM managers · as reported
← All 13F filers·← QuantOrb.pro
How to read Δ QoQ — the five insight categories, and the caveats
The categories. Analysts, quants and retail traders look past total portfolio value to isolate actionable signals. Five categories matter.
Conviction & concentration shifts
New positions vs complete exits — a brand-new stock signals high conviction; a full liquidation suggests a broken thesis or tax-loss harvesting. Aggressive sizing — look at share count, not dollars: a 20% share increase during a drawdown is strong dip-buying. Concentration — a narrowing top-5/10 means conviction; spreading capital across more names means hedging.
Sector & macro allocation rotations
Aggregating Δ QoQ moves across sectors shows where smart money is leaning in or sneaking out — rotating out of growth into defensives or energy, for example. The fund's total long equity exposure quarter-over-quarter is a proxy for overall institutional risk appetite.
Crowding & smart-money consensus
When several managers initiate or expand the same stock in the same quarter, that is institutional consensus. Contrarian reads: top pickers buying hard into a beaten-down name the market is selling.
Derivative & option overlays
Reported call/put changes indicate whether managers are adding downside hedges or leveraging upside exposure. Note: a long increase may be half of a market-neutral pair trade.
Who reads this
| Retail "cloners" | High-conviction ideas to replicate ~45 days after quarter-end. |
| Corporate IR | Which funds bought or dumped the stock, before the next call. |
| Quant / algo traders | Cross-sectional factor inputs: flow, momentum, ownership. |
Four caveats before you trade on it
- 45-day lag — holdings are quarter-end; positions may already be closed.
- Long-only — 13Fs miss shorts, pair trades and cash.
- No non-US / fixed income — the picture is US equities plus options.
- Corporate actions — splits and spinoffs distort raw share deltas.
Newsletter signup
Free subscription. Daily trading day morning dispatch. No spam.